RedHill Biopharma ( (RDHL) ) just unveiled an announcement.
RedHill Biopharma has entered into an exclusive licensing agreement with Hyloris Pharmaceuticals for the worldwide commercialization of RHB-102, excluding North America. The deal includes up to $60 million in potential milestone payments and royalties. This agreement allows Hyloris to develop and commercialize RHB-102, a once-daily extended-release formulation of ondansetron, for oncology support and gastrointestinal indications outside the U.S. Recent positive advice from the UK MHRA supports a potential UK Marketing Authorization Application for RHB-102, which could become the first oral 24-hour extended-release ondansetron for chemotherapy-induced nausea and vomiting. This partnership highlights RedHill’s strategic focus on expanding its R&D pipeline and leveraging collaborations to enhance its market position.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology. The company promotes Talicia® for treating Helicobacter pylori infection and has several key clinical programs, including opaganib for various indications and RHB-107 for broad applications.
YTD Price Performance: -24.69%
Average Trading Volume: 14,257
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.14M
Learn more about RDHL stock on TipRanks’ Stock Analysis page.